Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan 3rd-Quarter Profit Edges Down; Weighs Options for Obesity Segment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2012 | 03:07pm CET
   By Tess Stynes 
 

Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox.

Since the end of the quarter, Allergan said it is exploring strategic options for its obesity intervention business, including among other things, a potential sale of the unit.

For the year, the company raised the lower end of its guidance and now expects per-share earnings of $4.17 and $4.19 on product sales of $5.7 billion to $5.8 billion. Its prior view was for per-share profit of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion.

For the current quarter, Allergan forecast per-share earnings of $1.18 to $1.20 on revenue of $1.47 billion to $1.55 billion. Analysts polled by Thomson Reuters most recently expected $1.20 and $1.51 billion, respectively.

Chief Executive David E.I. Pyott in August had commented that the company is watching carefully for signs of economic vulnerability, but doesn't see a threat to long-term goals. Allergan's cosmetic medical products seem to appeal to people with greater economic means and purchasing power, providing some shelter from economic turmoil, he said at the time.

Allergan reported a profit of $249.4 million, down from $249.8 million a year earlier. On a per-share basis, earnings were up at 82 cents from 81 cents amid fewer shares outstanding. Excluding acquisition and restructuring related charges and other items, earnings were up at $1.06 from 92 cents.

Revenue increased 6.4% to $1.41 billion. Product net sales were up 6.1% to $1.39 billion, and were up 9.4% excluding currency impacts.

The company in August forecast per-share earnings of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 billion.

Gross margin rose to 86.7% from 85.8% amid the increased revenue.

Sales of Botox, which is used as a medical treatment and wrinkle-fighting cosmetic tool, rose 8.8% to $431.6 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue-increased 8.1%, or roughly 11% excluding currency fluctuations.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
12/06 CELLCEUTIX : CTIX) Advances Pipeline toward Multi-billion Dollar Opportunities, ..
12/05 ALLERGAN, INC. : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds ..
12/05 ALLERGAN : FDA clearance for Allergan's refractory glaucoma treatment
12/05 ALLERGAN : Zydus cadila settles patent case
12/03 CADILA HEALTHCARE : Zydus announces settlement of patent litigation
12/03 ALLERGAN, INC. : Pomerantz Law Firm Reminds Shareholders with Losses on their In..
12/02 ALLERGAN PLC (NYSE : AGN) Files An 8-K Regulation FD Disclosure
12/02 ALLERGAN PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form..
12/02 Pharma execs weigh in on possible changes under Trump
12/01 ALLERGAN, INC. : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds ..
More news
Sector news : Pharmaceuticals - NEC
09:09a PFIZER : Britain fines Pfizer record $107 million for huge drug price hike
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chairman & President
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Maria Teresa Hilado Director
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results